Diclazepam
1Provenance card
the boundary, as counts
Sources
3227 with DOI
3 strong · 20 moderate · 9 weak
Compilations
12026-05-09T15:33:10.668Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
33last ruled 2026-06-04
1 awaiting a ruling
Issued documents
42026-10-19T20:31:30.770Z
notice · info card · emergency
Searches
164 with no results
queries and counts on the build
Claims checked
8350 supported
50 supported · 33 not
Correspondence
0received
consent field ships in Phase 4
Edges
259
derivations recorded for this entity
Complete over 32 sources, 1 compilation, and 33 decisions.Not here: the private journal (never); 1 proposal awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/diclazepam/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued info_card
- 2026-10-02srcDesigner Benzodiazepines: A Review of Published Data and Public Health Significance
- 2026-10-02srcCharacterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics.
- 2026-10-02srcDetectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays
- 2026-10-02srcCharacterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864)
- 2026-10-02srcDesigner Benzodiazepines: Another Class of New Psychoactive Substances.
- 2026-10-02srcDesigner drugs: mechanism of action and adverse effects
- 2026-10-02srcThe blood-to-plasma ratio and predicted GABAA-binding affinity of designer benzodiazepines
- 2026-10-02srcAssessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances-Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam-in the UK
- 2026-10-02srcUrine analysis of 28 designer benzodiazepines by liquid chromatography-high-resolution mass spectrometry
- 2026-10-02srcOrgan distribution of diclazepam, pyrazolam and 3-fluorophenmetrazine
- 2026-10-02srcBenzodiazepines and Related Sedatives.
- 2026-10-02srcDiscriminative stimulus and reinforcing effects of diclazepam in rodents.
- 2026-10-02srcThe use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines
- 2026-10-02srcDesigner benzodiazepines versus prescription benzodiazepines: can structural relation predict the next step?
- 2026-10-02srcDesigner benzodiazepine dependence and the difficulties of outpatient management; a case report.
- 2026-10-02srcDesigner benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017.
- 2026-10-02srcFast and Sensitive Method for the Determination of 17 Designer Benzodiazepines in Hair by Liquid Chromatography-Tandem Mass Spectrometry
- 2026-10-02srcA Case Study Involving U-47700, Diclazepam and Flubromazepam-Application of Retrospective Analysis of HRMS Data
- 2026-10-02srcValidation of an LC-MS/MS Method for the Quantification of 13 Designer Benzodiazepines in Blood.
- 2026-10-02srcOverdose from designer benzodiazepine Diclazepam.
- 2026-10-02srcChallenges of Diagnosing and Managing Designer Benzodiazepine Dependence and Withdrawal: A Case Report.
- 2026-10-02srcProbe Electrospray Ionization Tandem Mass Spectrometry for the Detection and Quantification of Benzodiazepines
- 2026-10-02srcClinical Management of Designer Benzodiazepine Intoxication: A Systematic Review.
- 2026-10-02srcMetabolic interactions of benzodiazepines with oxycodone ex vivo and toxicity depending on usage patterns in an animal model.
- 2026-10-02src'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports
- 2026-10-02srcGABA-A receptor subtypes and benzodiazepine use, misuse, and abuse
- 2026-10-02srcThe Psychonauts' Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity.
- 2026-10-02srcFlumazenil: a benzodiazepine antagonist.
- 2026-10-02srcCouncil Decision (EU) 2024/832 of 4 March 2024 - EU scheduling of diclazepam
- 2026-10-02srcFederal Register: Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
- 2026-10-02srcDiclazepam physical and chemical properties
- 2026-10-02srcFederal Register: Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-07-03proposaldependence · taper
- 2026-06-04proposal30 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-05-09revisionRevision 1
- 2026-05-09absenceSearched ClinicalTrials.gov for "diclazepam benzodiazepine" — no results
- 2026-05-09absenceSearched PubMed for "diclazepam Ro5-3448 synthesis Sternbach benzodiazepine discovery" — no results
- 2026-05-09absenceSearched ClinicalTrials.gov for "diclazepam benzodiazepine" — no results
- 2026-05-09absenceSearched PubMed for "diclazepam metabolism metabolites CYP delorazepam lorazepam" — no results
- 2026-05-09genGeneration — pipeline-v5 · with 3 morepipeline-v5
- 2026-05-09rungeneration run
The same entries, as forms: six forms.